Latest News
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
Approximately 300,000 Canadians are living with IBD, with the number projected to grow to 470,000 by 2035. 1
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients with major depressive disorder (MDD)....
These outstanding growth stocks are worth buying on the dip.
One Ultra-Cheap High-Yield Dividend Stock to Buy
Now may be a good time for dividend investors to consider loading up on this stock.
There are very good reasons that stocks generally gain in value after a company receives orphan drug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36% after the announcement of an orphan designation. The impact was...
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time
There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock price of a company increased by 3.36%...
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion...
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
One of these high-yield pharma stocks stands out as a better buy right now.
2 Ultra-Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are attractive buys right now.
Why Shares of Innate Pharma Jumped Thursday
The company's collaboration agreement with Sanofi could soon pay off.
We are looking for publicly listed Japanese companies with strong growth prospects and sustainable dividends
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of...
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16...
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
Takeda ( TSE:4502/NYSE:TAK ) today announced that 21 new U.S. non-profit organizations have received grants as part of the company’s $19.5 million commitment to its FY2022 Corporate Social Responsibility program. Combined with its initial...
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
Takeda ( TSE:4502/NYSE:TAK ) today confirmed that the New England Journal of Medicine ( NEJM ) has published positive data from the Phase 4 EARNEST study of vedolizumab for the treatment of chronic pouchitis. The NEJM article is titled “...
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda ( TSE:4502/NYSE:TAK ) announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147 th Ordinary Meeting of Shareholders on June 28 th , 2023. The new candidate, Miki...
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200 th plasma donation center in the United States (U.S.)., with new locations in West Springfield, Mass. and Pearland, Texas. This...
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield.
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
Takeda ( TSE:4502/NYSE:TAK ) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The...
Should You Give Up on Novavax?
After a spectacular 2020 performance, Novavax's shares have plummeted.
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
These two high-yield dividend stocks are trading at bargain-basement prices.
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Takeda ( TSE:4502/NYSE:TAK ) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower...